Sophie Knipper1, Derya Tilki2, Joost Mansholt1, Christoph Berliner3, Christian Bernreuther3, Thomas Steuber1, Tobias Maurer1, Markus Graefen1. 1. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 2. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Electronic address: d.tilki@uke.de. 3. Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Abstract
The first results on 99mTechnetium prostate-specific membrane antigen-radioguided surgery (99mTc-PSMA- RGS) showed promising outcome. Here, we sought to evaluate if this targeted molecular surgical approach might be more effective than conventional salvage lymph node dissection (sLND). We prospectively analysed 42 consecutive patients who underwent sLND based on preoperative 68Gallium (68Ga)-PSMA-positron emission tomography (PET) imaging between 2015 and 2018. In 29 patients, the dissection field was based solely 68Ga-PSMA-PET imaging (conventional surgical approach [CSA]), whereas 13 patients underwent 99mTc-PSMA-RGS. Preoperative characteristics of both groups were similar. Final pathology revealed no metastases in nine CSA patients (31%), whereas all visible lesions on preoperative 68Ga-PSMA-PET were removed in patients who underwent RGS. A PSA decline in general, >50% and >90% within 6 wk was seen in 50%, 29%, and 7% versus 100%, 92%, and 53% in CSA versus RGS groups, respectively (all p<0.01). This is the first comparison of conventional and PSMA-radioguided approach with regards to short-term efficacy of sLND. Although long-term outcome needs to be awaited, RGS offers promising results. PATIENT SUMMARY: We compared two surgical approaches for lymph node dissection in lymph node only recurrent prostate cancer patients. The radioguided approach was superior in removing the affected lymph nodes, resulting in a more pronounced prostate-specific antigen decline.
The first results on 99mTechnetium prostate-specific membrane antigen-radioguided surgery (99mTc-PSMA- RGS) showed promising outcome. Here, we sought to evaluate if this targeted molecular surgical approach might be more effective than conventional salvage lymph node dissection (sLND). We prospectively analysed 42 consecutive patients who underwent sLND based on preoperative 68Gallium (68Ga)-PSMA-positron emission tomography (PET) imaging between 2015 and 2018. In 29 patients, the dissection field was based solely 68Ga-PSMA-PET imaging (conventional surgical approach [CSA]), whereas 13 patients underwent 99mTc-PSMA-RGS. Preoperative characteristics of both groups were similar. Final pathology revealed no metastases in nine CSApatients (31%), whereas all visible lesions on preoperative 68Ga-PSMA-PET were removed in patients who underwent RGS. A PSA decline in general, >50% and >90% within 6 wk was seen in 50%, 29%, and 7% versus 100%, 92%, and 53% in CSA versus RGS groups, respectively (all p<0.01). This is the first comparison of conventional and PSMA-radioguided approach with regards to short-term efficacy of sLND. Although long-term outcome needs to be awaited, RGS offers promising results. PATIENT SUMMARY: We compared two surgical approaches for lymph node dissection in lymph node only recurrent prostate cancerpatients. The radioguided approach was superior in removing the affected lymph nodes, resulting in a more pronounced prostate-specific antigen decline.
Authors: George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș Journal: Int J Mol Sci Date: 2022-04-30 Impact factor: 6.208
Authors: Carlo A Bravi; Nicola Fossati; Giorgio Gandaglia; Nazareno Suardi; Elio Mazzone; Daniele Robesti; Daniar Osmonov; Klaus-Peter Juenemann; Luca Boeri; R Jeffrey Karnes; Alexander Kretschmer; Alexander Buchner; Christian Stief; Andreas Hiester; Alessandro Nini; Peter Albers; Gaëtan Devos; Steven Joniau; Hendrik Van Poppel; Shahrokh F Shariat; Axel Heidenreich; David Pfister; Derya Tilki; Markus Graefen; Inderbir S Gill; Alexander Mottrie; Pierre I Karakiewicz; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2020-07-02 Impact factor: 24.267
Authors: Marieke J Krimphove; Lena H Theissen; Alexander P Cole; Felix Preisser; Philipp C Mandel; Felix K H Chun Journal: World J Mens Health Date: 2019-03-05 Impact factor: 5.400
Authors: Alexander Kretschmer; Johanna Milow; Chukwuka Eze; Alexander Buchner; Minglun Li; Thilo Westhofen; Frederik Fuchs; Paul Rogowski; Christian Trapp; Ute Ganswindt; Mathias Johannes Zacherl; Leonie Beyer; Vera Wenter; Peter Bartenstein; Boris Schlenker; Christian G Stief; Claus Belka; Nina-Sophie Schmidt-Hegemann Journal: Front Oncol Date: 2021-06-21 Impact factor: 6.244
Authors: Nina-Sophie Schmidt-Hegemann; Alexander Buchner; Chukwuka Eze; Paul Rogowski; Christian Schaefer; Harun Ilhan; Minglun Li; Wolfgang Peter Fendler; Peter Bartenstein; Ute Ganswindt; Christian Stief; Claus Belka; Alexander Kretschmer Journal: Strahlenther Onkol Date: 2020-03-24 Impact factor: 3.621
Authors: Yvonne H W Derks; Dennis W P M Löwik; J P Michiel Sedelaar; Martin Gotthardt; Otto C Boerman; Mark Rijpkema; Susanne Lütje; Sandra Heskamp Journal: Theranostics Date: 2019-09-20 Impact factor: 11.556